Branch Retinal Vein Occlusion
📧 Sign up to get email alerts when something new happens for Branch Retinal Vein Occlusion.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders [Phase 3]
Phase 3 trial assessing the safety of ONS-5010 in subjects with visual impairment due to retinal disorders completed with results posted.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders [Phase 3]
A Phase 3 trial comparing the safety of ONS-5010 when administered from vials versus pre-filled syringes in adults with retinal disorders ca…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration [Phase 1, Phase 2]
EyeBiotech Ltd reports a two-part Phase 1/Phase 2 clinical trial evaluating safety in macular edema due to branch retinal vein occlusion and…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Hoffmann-La Roche reports a real-world, observational study to gain clinical insights into Roche ophthalmology products across several retin…
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss [Phase 3]
A Phase III study comparing drug 601 to ranibizumab for vision loss due to branch retinal vein occlusion has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO [Phase 2]
A Phase 2 dose-masked trial evaluating intravitreal Eye103 in participants with neovascular age-related macular degeneration or macular edem…
-
CLINICAL_TRIALS trial_result · 2025-06-27Clinical Trial Update: 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) [Phase 2]
A Phase 2 clinical trial comparing drug candidate 601 to ranibizumab in patients with branch retinal vein occlusion has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders [Phase 3]
A 3-month Phase 3 safety study of ONS-5010 in subjects with visual impairment due to retinal disorders has completed.
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion [Phase 4]
Phase 4 trial update evaluating Eylea (aflibercept) and Lucentis (ranibizumab) for macular edema due to branch retinal vein occlusion. The t…
-
CLINICAL_TRIALS trial_result · 2024-01-18Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion [Phase 3]
Phase 3 trial evaluating Faricimab for macular edema secondary to branch retinal vein occlusion has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-07-28Clinical Trial Update: Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion [Phase 3]
Phase 3 trial comparing brolucizumab to aflibercept in visual impairment from macular edema due to branch retinal vein occlusion; the study …
-
CLINICAL_TRIALS trial_result · 2022-07-15Clinical Trial Update: Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion [Phase 3]
Phase 3 clinical trial update for conbercept ophthalmic injection in macular edema due to branch retinal vein occlusion completed.
-
FDA approval · 2022-06-09FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
The FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen, authorizing its use as a biosimilar to ranibizumab.
-
CLINICAL_TRIALS trial_result · 2022-05-24Clinical Trial Update: EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN) [Phase 3]
Phase 3 trial of a novel ocular antiseptic for diabetic macular edema and branch retinal vein occlusion was terminated.
-
CLINICAL_TRIALS trial_result · 2019-11-13Clinical Trial Update: Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions [Phase 2, Phase 3]
Retrospective study on the effectiveness and safety of niacin and steroid eye drops for retinal vein occlusions; the trial was terminated wi…
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision [Phase 4]
Phase 4 trial update for ranibizumab in macular edema due to branch retinal vein occlusion; study terminated.
-
CLINICAL_TRIALS trial_result · 2019-08-20Clinical Trial Update: Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion [Phase 4]
Phase 4 trial evaluating PRN ranibizumab regimen for macular edema caused by branch retinal vein occlusion has completed.
-
FDA approval · 2019-08-12FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
The FDA approved Regeneron's supplemental application for EYLEA (aflibercept), updating its labeling to reflect an expanded or modified indi…
-
CLINICAL_TRIALS trial_result · 2018-12-03Clinical Trial Update: Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT [Phase 2]
Phase 2 proof-of-concept study evaluating re-treatment with ranibizumab guided by OCT in branch retinal vein occlusion.
-
CLINICAL_TRIALS trial_result · 2018-11-14Clinical Trial Update: Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases [Phase 2]
Phase 2 clinical trial exploring non-damaging retinal laser therapy (PASCAL) for macular diseases; status and results not provided.
-
FDA approval · 2018-08-16FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
FDA has approved a supplemental application for EYLEA (aflibercept) from Regeneron Pharmaceuticals, Inc. The approval indicates the suppleme…
-
CLINICAL_TRIALS trial_result · 2017-05-08Clinical Trial Update: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) [Phase 3]
Phase 3 trial evaluating ranibizumab injections versus sham in patients with macular edema due to branch retinal vein occlusion; results pos…
-
CLINICAL_TRIALS trial_result · 2017-04-11Clinical Trial Update: Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion [Phase 4]
Phase 4 trial update evaluating widefield angiography-guided targeted-retinal photocoagulation with anti-VEGF injections for ischemic centra…
-
CLINICAL_TRIALS trial_result · 2017-03-10Clinical Trial Update: Ranibizumab Treatment for Retinal Vein Occlusion [NA]
This document concerns ranibizumab for macular edema due to branch retinal vein occlusion or central retinal vein occlusion. The trial statu…
-
CLINICAL_TRIALS research · 2017-03-01Clinical Trial Update: Observation of Treatment Patterns With Lucentis in Approved Indications
An observational study examining how Lucentis is used in approved indications such as neovascular age-related macular degeneration and diabe…